Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ402C)

Drug Name
L-768673 Drug Info
Synonyms L-768673; CHEMBL16900; SCHEMBL7207125; BDBM50061209; LS-28521; l-768,673
Cross-matching ID
PubChem CID
9851380
CAS Number
CAS 177954-68-6
TTD Drug ID
DMZ402C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Voltage-gated potassium channel Kv7.1 (KCNQ1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indapamide DMGN1PW Edema MG29 Approved [2]
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [3]
XE991 DMLH1PK Discovery agent N.A. Investigative [4]
N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide DM6EJQ4 Discovery agent N.A. Investigative [5]
(3R,4S)-293B DM47BEG Discovery agent N.A. Investigative [6]
HMR-1556 DMXMTA9 Discovery agent N.A. Investigative [7]
R-L3 DMGEDQJ Discovery agent N.A. Investigative [8]
3S,4R-293B DMVGDSM Discovery agent N.A. Investigative [6]
N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide DMEUXOQ Discovery agent N.A. Investigative [5]
L-735,821 DMY60MG Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv7.1 (KCNQ1) TT846HF KCNQ1_HUMAN Inhibitor [1]

References

1 Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8.
2 Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
3 Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
4 Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23.
5 Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
6 A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
7 Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
8 A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30.
9 Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol. 2003 Jul;64(1):70-7.